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The relative contribution of human cytomegalovirus (HMCV)especiﬁc CD4þ and CD8þ T cells to the control of
HCMV infection in hematopoietic stem cell transplant (HSCT) recipients is still controversial. HCMV
reactivation and HCMV-speciﬁc CD4þ and CD8þ T cell reconstitution were monitored for 1 year in 63 HCMV-
seropositive patients receiving HSCT. HCMV reactivation was detected in all but 2 patients. In 20 of 63 (31.7%)
patients (group 1) HCMV infection resolved spontaneously, whereas 32 of 63 (50.8%) patients (group 2)
controlled the infection after a single short-course of pre-emptive therapy and the remaining 9 (14.3%) pa-
tients (group 3) suffered from relapsing episodes of HCMV infection, requiring multiple courses of antiviral
therapy. The kinetics and magnitude of HCMV-speciﬁc CD8þ T cell reconstitutionwere comparable among the
3 groups, but HCMV-speciﬁc CD4þ T cells were lower in number in patients requiring antiviral treatment.
HCMV-seronegative donors, as well as unrelated donors (receiving antithymocyte globulin) and acute graft-
versus-host disease (GVHD) were associated with both delayed HCMV-speciﬁc CD4þ T cell reconstitution and
severity of infection. Conversely, these risk factors had no impact on HCMV-speciﬁc CD8þ T cells. Eight
patients with previous GVHD suffered from HCMV gastrointestinal disease, although in the presence of
HCMV-speciﬁc CD4þ and CD8þ systemic immunity and undetectable HCMV DNA in blood. Reconstitution of
systemic HCMV-speciﬁc CD4þ T cell immunity is required for control of HCMV reactivation in adult HSCT
recipients, but it may not be sufﬁcient to prevent late-onset organ localization in patients with GVHD. HCMV-
speciﬁc CD8þ T cells contribute to control of HCMV infection, but only after HCMV-speciﬁc CD4þ T cell
reconstitution.
 2015 American Society for Blood and Marrow Transplantation.þ þINTRODUCTION
Human cytomegalovirus (HCMV) infection remains a
signiﬁcant cause of morbidity and mortality after hemato-
poietic stem cell transplantation (HSCT). Although ganciclo-
vir (GCV) prophylaxis and pre-emptive therapy effectively
reduce the risk of HCMV disease, a minority of patients still
develop recurrent episodes of HCMV reactivation and end-
organ disease [1]. Since the 1980s, it has been known thatedgments on page 2201.
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ty for Blood and Marrow Transplantation.the reconstitution of HCMV-speciﬁc CD4 and CD8 T cells is
required to confer protection against HCMV reactivation
[2,3]. Donor HCMV seronegativity, recipient HCMV seropos-
itivity, T cell depletion, and the use of high-dose corticoste-
roids as treatment against graft-versus-host disease (GVHD)
are among the factors inﬂuencing the recovery of HCMV-
speciﬁc T cell immunity after HSCT [4,5].
To better deﬁne the role of both HCMV-speciﬁc CD4þ and
CD8þ T cells in the control of HCMV infection after HSCT, we
used HCMV-infected immature dendritic cells [6] for ex vivo
stimulation of HCMV-speciﬁc T cells in a population of adult
allogeneic HSCT recipients (HSCTR). The main objective of
this study was to correlate the recovery of HCMV-speciﬁc
immunity in this population with different clinical
Table 1
Characteristics of the 63 HSCTR
Characteristic n (%)
Gender
Male 37 (59)
Female 26 (41)
Age at transplantation, median (range), yr 53 (26-68)
Underlying disease
Acute myeloid leukemia 30 (48)
Myelodysplastic syndrome 9 (14)
Acute lymphocytic leukemia 7 (11)
Non-Hodgkin lymphoma 5 (8)
Chronic lymphocytic leukemia 4 (6)
Myeloﬁbrosis 4 (6)
Multiple myeloma 3 (5)
Chronic myelomonocytic leukemia 1 (2)
Disease status at transplantation
Complete remission 38 (60)
Partial remission 2 (3)
Active disease 22 (35)
Front line 1 (2)
Myeloablative (chemotherapy based) conditioning regimen
Standard intensity 19 (30)
Reduced intensity 44 (70)
ATG administration 38 (60)
Stem cell source
Peripheral blood 51 (81)
Bone marrow 12 (19)
Donor type
Sibling 26 (42)
Unrelated 37 (58)
Donor/recipient HCMV serostatus
Dþ/Rþ 46 (73)
D/Rþ 17 (27)
GVHD
No acute or chronic GVHD 30 (48)
Acute (grade I-II) 16 (25)
Acute (grade III-IV) 9 (14)
Chronic 12 (19)
D indicates donor; R, recipient.
E. Gabanti et al. / Biol Blood Marrow Transplant 21 (2015) 2192e2202 2193presentations of HCMV infection: (1) immune control of
HCMV infection, (2) initial lack of immune control of HCMV
infection followed by short duration pre-emptive antiviral
treatment, and (3) sustained lack of immune control of
HCMV infection requiring multiple courses of pre-emptive
antiviral therapy. In addition, we studied the impact of risk
factors on the differential recovery of HCMV-speciﬁc CD4þ
and CD8þ T cell responses and severity of HCMV infection.
Finally, we analyzed the role of peripheral blood immunity in
preventing HCMV gastrointestinal (GI) disease (GID). Results
of the present study indicate that recovery of HCMV-speciﬁc
CD4þ T cells is mandatory for control of systemic HCMV
infection, but it may not be sufﬁcient to avoid late-onset GID.
METHODS
Study Population
From June 2011 through May 2014, 77 HCMV-seropositive patients
receiving HSCTat Fondazione IRCCS Policlinico SanMatteo, Pavia, Italy, were
enrolled in the study. Fourteen patients were lost to follow-up because of
early (within 3 months) death not related to HCMV infection (n ¼ 7) or
underlying disease relapse (n ¼ 3), systemic HCMV infection at the time of
transplantation (n ¼ 1), or post-transplantation follow-up performed in
other centers (n¼ 3). Thus, 63 patients, with a median follow-up of 358 days
(range, 90 to 483) were analyzed. Their characteristics are shown in Table 1.
GVHD prophylaxis and treatment were previously reported [7]. Patients
with steroid-resistant GVHD were treated with extracorporeal photo-
chemotherapy (hepatic GVHD), mofetil mycophenolate, or inﬂiximab (gut
disease).
Thirty HCMV-seropositive adult healthy subjects were used as controls.
The study was approved by the Fondazione IRCCS Policlinico San Matteo
bioethics committee and institutional review board (Protocol n.
20100005053), and patients gave written informed consent before entering
the study.
Management of HCMV Infection
HCMV reactivation (virus detection in blood or tissue biopsies) and
disease (HCMV end-organ infection in association with clinical symptoms)
were diagnosed by real-time PCR [8,9]. HCMV DNAemia was determined
twice each week until discharge from the hospital, and then once each week
for the ﬁrst 3 months [8]. Subsequently, patients were monitored for HCMV
at scheduled medical visits or in the presence of HCMV-related clinical
symptoms. In patients receiving immunosuppressive therapy for acute
GVHD and/or after detection of HCMVDNA in blood, monitoring of DNAemia
was resumed twice each week.
No patient received anti-HCMV prophylaxis. Pre-emptive therapy was
administered with a HCMV DNAemia cutoff of 30,000 DNA copies/mL
whole blood, unless clinical conditions of patients suggested an earlier
initiation of treatment (10,000 copies/mL) [10], and consisted of admin-
istration of intravenous GCV (5 mg/kg twice each day), replaced by foscarnet
(90 mg/kg twice each day) in case of neutropenia. Antiviral treatment was
stopped after 2 consecutive DNA-negative blood samples. Biopsy-proven
HCMV GID was treated similarly until resolution of clinical symptoms
and/or endoscopic intestinal lesions.
Immunologic Monitoring
Immunological monitoring was performed before the pre-
transplantation myeloablative regimen, and at least at 30, 60, 90, 120, 180,
and 360 days after transplantation. Additional controls were performed in
patients with GVHD just before the onset of steroid treatment, a week after
and, in patients showing a decrease in HCMV-speciﬁc T cells, every 2 weeks
until recovery of HCMV-speciﬁc immunity. Subjects with protective virus-
speciﬁc cellular immunity were considered those with at least 1 HCMV-
speciﬁc CD4þ and 3 HCMV-speciﬁc CD8þ T cells/mL blood [7,11].
Total and HCMV-speciﬁc T cells were determined by ﬂow cytometry
analysis as reported [6,12] and are summarized in the Supplementary
Methods.
Statistical Analysis
The number of total or HCMV-speciﬁc T cells between 2 groups were
compared by using the Mann-Whitney U-test. The Kruskall-Wallis test was
used to compare more than 2 groups, with Dunn’s post test and correction
for multiple comparisons. The association of different factors (age, GVHD,
donor type, and serostatus) with the severity of HCMV infection was
analyzed by the chi-square test. Time to HCMV-speciﬁc T cell reconstitutionwas calculated using Kaplan-Meier curves, which were compared by the
log-rank test.RESULTS
HCMV Infection Reactivation and T Cell Immune
Reconstitution
Three groups of patients were identiﬁed
The 63 patients were divided into 3 groups on the basis of
the severity of systemic HCMV infection and the relevant
requirement for pre-emptive therapy (Table 2). The devel-
opment of late-onset GID, which occurred in some patients
in complete dissociation from systemic infection and
regardless of peripheral blood T cell recovery, is analyzed
separately (see below).
Three representative cases are reported in Figure 1A-C.
Group 1 included 20 of 22 patients who developed self-
resolving systemic HCMV infection (SI) without reaching
the established cut-off of 30,000 HCMV DNA copies/mL
blood. The median viral load peak was 2400 (range, 0 to
11,200) copies/mL blood andwas reached at amedian time of
53 (range, 26 to 270) days after transplantation (Table 2).
However, 3 of these patients developed late-onset (between
6 and 12 months after HSCT) HCMV GID in the absence of
detectable virus in blood (see below), whereas 2 patients had
no detectable infection throughout the study period.
Group 2 included 32 patients who underwent a single
course of antiviral therapy for SI either reaching (n ¼ 23) or
approaching (n ¼ 9) the cut-off of 30,000 copies/mL. The
median viral load peak was 37,100 (range, 10,300 to 100,000)
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E. Gabanti et al. / Biol Blood Marrow Transplant 21 (2015) 2192e22022194copies/mL at amedian time of 45 (range, 25 to 124) days after
transplantation (Table 2). Median duration of antiviral pre-
emptive therapy was 26 (range, 9 to 49) days. GCV therapy
controlled SI in all patients. However, 3 patients developed
late-onset GID in the absence of virus in blood.
Group 3 included 9 patients, who underwent multiple
courses of antiviral pre-emptive therapy because of relapsing
systemic infection reaching or exceeding the cutoff. The
median viral load peakwas 69,300 (range,16,200 to 203,900)
copies/mL at a median time of 47 (range, 33 to 52) days after
transplantation. Two patients underwent antiviral therapy
before reaching this threshold, based on medical decision. As
reported in Table 2, the total median duration of antiviral
therapy was 66 (range, 44 to 180) days. Two patients also
suffered from late-onset GID (with very low level or absent
virus in blood).
Risk factors for HCMV infection severity were also
investigated (see Supplementary Results).Kinetics of Total and HCMV-Speciﬁc CD4þ and CD8þ
T Cells in the 3 Groups of Patients
In group 1, median level of total CD4þ T cells at day þ60
(the time point nearest to the infection peak) was 310 (range,
51 to 1036) cells/mL and did not change signiﬁcantly until
1 year after transplantation, never reaching levels of healthy
controls (Supplemental Figure 1A). At day 60, total CD8þ
Tcells (409 [range, 245 to 1717] cells/mL) were already similar
to controls, and remained stable until 1 year after trans-
plantation (611 [range, 88 to 2270] cells/mL), as illustrated in
Supplemental Figure 1B.
In group 2, median level of total CD4þ T cells at day þ60
was 95 (range, 16 to 480) cells/mL, signiﬁcantly lower than in
group 1 patients, reaching comparable values 4 to 6 months
after transplantation (Supplemental Figure 1A). At day þ60,
total CD8þ T cells (513 [range, 32 to 986] cells/mL) were not
different from group 1 patients. These cells progressively
increased until 1281 (range, 206 to 4445) cells/mL 1 year after
transplantation (Supplemental Figure 1B).
Almost all group 3 patients showed levels of total CD4þ
T cells under 100 cells/mL until 4 months after trans-
plantation. Only 4 of 9 (55%) of these patients exceeded this
level at 6 months after transplantation (Supplemental
Figure 1A). Conversely, at day þ60, median total CD8þ
T cells (371 [range, 74 to 808] cells/mL) were not signiﬁcantly
different from controls and from total CD8þ T cells of group 1
patients, remaining stable throughout follow-up (594 [range,
181 to 7789] cells/mL at 12 months), as shown in
Supplemental Figure 1B.
As for HCMV-speciﬁc immunity of group 1 patients
(Table 2), HCMV-speciﬁc CD4þ T cells were comparable to
control levels, and thus were near or above the cut-off of 1
HCMV-speciﬁc T cell/mL, starting from day þ60 through
dayþ360 (Figure 2A). HCMV-speciﬁc CD8þ Tcells (Figure 2B)
showed high levels, superior to those of healthy controls,
from day þ60 throughout the follow-up.
In group 2, HCMV-speciﬁc CD4þ T cells were signiﬁcantly
lower than in group 1 patients (Table 2). Yet, 4 months after
transplantation, 8 of 29 (27%) patients had speciﬁc-CD4þ
T cells below the cut-off of 1 cell/mL (Figure 2A). Almost all
group 2 patients exceeded the cut-off 6 months after trans-
plantation. HCMV-speciﬁc CD8þ T cells (Figure 2B) were
lower than those of healthy controls and group 1 patients
until day þ60; afterwards levels of HCMV-speciﬁc CD8þ
T cells were superior to controls and similar to group 1.
Figure 1. Kinetics of total and HCMV-speciﬁc CD4þ and CD8þ T cells in 3 representative HSCTR patients, 1 for each group. Panel A (group 1 patient): self-resolving
infection in the presence of low viral load and HCMV-speciﬁc CD4þ and CD8þ T cells above the cut-off thresholds. Panel B (group 2 patient): HCMV infection GCV-
treated for viral load above the cut-off, with undetectable HCMV-speciﬁc CD4þ T cells until day 120, when they exceeded the cut-off level indicating control of HCMV
infection. Panel C (group 3 patient): recurrent infections in a patient treated twice for systemic infection (viral load above the cut-off). This patient received steroids
and extracorporeal photochemotherapy as anti-GVHD treatment. HCMV-speciﬁc CD4þ T cells showed levels below the cut-off until 6 months after transplantation.
GCV, ganciclovir, FOS, foscarnet, ECP, extracorporeal photochemotherapy.
E. Gabanti et al. / Biol Blood Marrow Transplant 21 (2015) 2192e2202 2195In group 3 patients (Table 2), HCMV-speciﬁc CD4þ T cells
were almost absent at day 60, and 6 months after trans-
plantation they were still below the cut-off of 1 cell/mL in
nearly all patients (Figure 2A). Strikingly, HCMV-speciﬁc
CD8þ T cells (Figure 2B) were at high levels, comparable to
those of healthy controls and group 1 patients throughout
the follow-up.
Polyfunctional analysis of HCMV-speciﬁc CD4þ and CD8þ
T cells is described in the Supplementary Results
(Supplemental Figure 2), indicating that patients of group 2
developing HCMV infection requiring treatment in the
presence of HCMV-speciﬁc CD4þ T cells show a lower
frequency of CD4þ T cells producing IL-2 and TNFa together
with IFN-g than patients controlling the infection. On the
contrary, the expression of perforin by HCMV-speciﬁc T cells
was high in all patients examined (median, 87%; range, 63%
to 100% and median, 95%; range, 52% to 100% of HCMV-
speciﬁc CD4þ and CD8þ T cells, respectively) and did not
discriminate between patients controlling or not the
infection.
Factors Associated With Speciﬁc T Cell Immunity
Reconstitution
The same factors associated with severity (Supplemental
Table 1) of HCMV infection (unrelated donor/use of antith-
ymocyte globulin [ATG], HCMV-seronegative donor, and
acute GVHD) were also associated with delayed HCMV-
speciﬁc CD4þ T cell reconstitution (Figure 3). In particular, a
strong correlation was found between donor HCMV seros-
tatus and HCMV-speciﬁc CD4þ T cell recovery (Figure 3B): ie,1 year after transplantation, 5 of 13 (38%) donor negative/
recipient positive patients were found to not have recon-
stituted HCMV-speciﬁc CD4þ Tcells above the protective cut-
off, when the majority (32 of 40, 80%) of donor positive/
recipient positive HSCTR already reconstituted HCMV-
speciﬁc CD4þ T cells 90 days after transplantation. In
contrast, no parameter inﬂuenced the reconstitution of
HCMV-speciﬁc CD8þ T cells (data not shown).
To better determine the impact of the steroid treatment
for acute GVHD on HCMV-speciﬁc T cell immunity, the 25
HSCTR who suffered from acute GVHD were divided into 2
subgroups, according to the development of acute GVHD
before or after the reconstitution of detectable levels of
HCMV-speciﬁc CD4þ T cells (Figure 4).
The ﬁrst subgroup (Figure 4A,B) included 15 patients
starting steroid therapy at a median time of 17 days (range, 9
to 52) after transplantation, when HCMV-speciﬁc CD4þ
T cells were not yet detected. Median onset of antiviral
therapy (administered in 13 of 15 patients) was at day 46
(range, 28 to 146). In this case, it was found that the time
required to restore HCMV-speciﬁc CD4þ T cells was signiﬁ-
cantly (P ¼ .04) longer than in patients without GVHD
(Figure 4A). No signiﬁcant difference (P ¼ .35) was found
with respect to HCMV-speciﬁc CD8þ T cell reconstitution
between patients with and without GVHD (Figure 4B).
The second subgroup (Figure 4C,D) included 10 patients
starting anti-GVHD therapy at a median time of 45 days
(range, 25 to 114) after transplantation, when HCMV-speciﬁc
CD4þ T cell immunity was already detectable. Median onset
of antiviral therapy for these patients was at day 52 (range,
Figure 2. Kinetics of HCMV-speciﬁc (A) CD4þ and (B) CD8þ T cells in the 3 groups of HSCTR. Statistical signiﬁcance of the differences between the 3 groups of patients
is reported as follows: *P < .05; **P < .01; ***P < .001; ****P < .0001.
E. Gabanti et al. / Biol Blood Marrow Transplant 21 (2015) 2192e2202219647 to 124). Steroid treatment determined a strong decrease
(greater than 60% compared with presteroid immunity) in
HCMV-speciﬁc CD4þ T cells in patients belonging to groups 2
and 3 with HCMV SI requiring antiviral treatment. In patients
who had recurrent infections (group 3), low levels of HCMV-
speciﬁc CD4þ T cells persisted for at least 3 months after
onset of therapy. In 2 of 4 patients of group 1, steroid therapy
caused a reduction in HCMV-speciﬁc CD4þ T cells, which,
however, remained above the protective cut-off level
(Figure 4C). The other 2 group 1 patients, who received ste-
roids for GVHD treatment at a very low dosage, maintained
speciﬁc CD4þ immunity at the presteroid level and surpassed
the protective cut-off level within a few weeks. Steroid
therapy for GVHD had no substantial impact on HCMV-
speciﬁc CD8þ T cell level (Figure 4D).
It was also investigated whether steroid treatment
determined a reduction in some speciﬁc functional subset of
HCMV-speciﬁc CD4þ T cells. Results showed that multi-
functional and monofunctional CD4þ T cells decreased in
parallel (data not shown).Some patients received extracorporeal photo-
chemotherapy (FEC), mofetil mycophenolate (MMF), or
inﬂiximab as second-line GVHD treatment. Among these, 3
patients received FEC before and 11 patients after immune
reconstitution. Only in 3 patients we observed a reduction in
HCMV-speciﬁc CD4þ T cells (along with speciﬁc CD8þ T cells
in 2 cases) followed by HCMV reactivation. No signiﬁcant
change in HCMV-speciﬁc T cells was observed in the other
cases, as well as in the 8 patients receiving MMF. Finally, in 1
patient receiving inﬂiximab in association with FEC, a
reduction in HCMV-speciﬁc CD4þ T cells was observed
without subsequent HCMV reactivation.
HCMV GID
All patients suffering from GID were endoscopically bio-
psied. HCMV organ localization was diagnosed in 8 of 63
patients (13%) on the basis of HCMV DNA quantiﬁcation in
organ biopsies (Table 3). For each patient, multiple biopsies
of the upper and lower GI tract were taken: in Table 3 bi-
opsies with the highest viral load are listed, along with
Figure 3. Kinetics of HCMV-speciﬁc CD4þ T cells in HSCTR patients receiving stem cells (panel A) from sibling or unrelated donors, or (panel B) from HCMV-
seropositive or seronegative donors and (panel C) with/without GVHD. Statistical signiﬁcance of the differences between the 2 groups of patients reported in
each panel is as follows: *P < .05; **P < .01; ***P < .001; ****P < .0001.
E. Gabanti et al. / Biol Blood Marrow Transplant 21 (2015) 2192e2202 2197
Figure 4. Kaplan-Meier curves represent time to reconstitution of HCMV-speciﬁc (A) CD4þ and (B) CD8þ T cells in 15 HSCTR with GVHD versus 30 without GVHD.
Censored patients of the 3 groups are represented with different colors. P values of the log-rank test are shown. In panels (C) and (D) kinetics of HCMV-speciﬁc CD4þ
and CD8þ T cells in 10 HSCTR patients steroid-treated for GVHD and with presteroid immunity, are reported.
E. Gabanti et al. / Biol Blood Marrow Transplant 21 (2015) 2192e22022198HCMV-related symptoms and antiviral therapy duration. GID
developed at a median time of 325 days (range, 144 to 387)
after transplantation: at this time, nearly all patients (except
patients number 14 and 38) had protective levels of HCMV-
speciﬁc CD4þ T cells (median value, 6.7 cells/mL blood) and
HCMV-speciﬁc CD8þ immunity was largely above theprotective cut-off (median value, 123.8 cells/mL). At the time
of organ infection diagnosis, viral DNA in blood was negative
for 3 to 9 months before (6 patients) or reached very low
levels after a recent reactivation. Moreover, in terms of cy-
tokines and perforin production, we observed that HCMV-
speciﬁc CD4þ and CD8þ T cells were as functional as in
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E. Gabanti et al. / Biol Blood Marrow Transplant 21 (2015) 2192e2202 2199patients who were HCMV disease-free (data not shown). At
the time of GID, all HSCTR were receiving low-dosage
methylprednisolone (.25 to 1 mg/kg/day); in 3 cases in as-
sociation with FEC and MMF, in other 2 cases with FEC or
MMF only. Five patients were still receiving cyclosporine A.
All patients (except patient numbers 14 and 31) underwent
this treatment for chronic GVHD (intestinal, cutaneous, or
hepatic, either occurring de novo or after acute GVHD).
However, the ﬁrst diagnosis of GVHD occurred at a median
time of 79 (range, 27 to 225) days after transplantation, be-
tween 4 and 10 months before detection of HCMV in organ
biopsies (Table 3) and no sign of active GVHD (ie, presence of
apoptotic bodies) were observed in GI biopsies at the time of
diagnosis of HCMV-GID. In addition, 6 of 8 patients (75%)
received HSCT from an HCMV-seronegative donor. All pa-
tients, except patient number 13 (died from intestinal sur-
gery complications) and patient number 14 (died of
neurotoxoplasmosis) recovered completely after antiviral
therapy and were alive 1 year after transplantation.
DISCUSSION
In this study, we adopted a method involving the use
of HCMV-infected autologous dendritic cells (DC) for T cell
stimulation, and enabled the simultaneous and compre-
hensive determination of HCMV-speciﬁc CD4þ and CD8þ
T cells [6], to investigate the contribution provided by both
arms of T cell immunity to the control of HCMV infection in
adult HSCTR. This method allows the detection of T cells
speciﬁc for multiple HCMV antigens as naturally presented
by infected DC. Instead, the more common use of peptide
pools from individual viral proteins (such as pp65 and IE-1),
although permitting a rapid and easier monitoring of HCMV-
speciﬁc T cells, underestimates the actual T cell immune
response against the virus [12]. On the other hand, we
observed a similar polyfunctional proﬁle in healthy donors’
T cells stimulated by infected DC, infected cell lysate, or
peptide pool [13]. Thus, it is possible to compare the quality
of the T cell response obtained with infected DC or other
methods.
Indeed, some authors consider CD8þ T cells to play a
major role in the protection against HCMV reactivation
[14,15], while a few others indicate that HCMV-speciﬁc CD4þ
T cells are required to provide protection [16,17]. The present
study demonstrates the following: (1) HCMV-speciﬁc CD8þ
T cell reconstitution after HSCT is not sufﬁcient to protect
against HCMV reactivation, if not associated with HCMV-
speciﬁc CD4þ T cell reconstitution; (2) control of HCMV
infection is better achieved in the presence of polyfunctional
HCMV-speciﬁc CD4þ T cells simultaneously producing IFN-g,
TNFa, and IL-2; (3) GVHD occurrence and the relevant high-
dose steroid treatment, as well as transplantation from a
HCMV-seronegative or unrelated donor (the latter is
associated with ATG treatment), are risk factors for HCMV
reactivation that have a major impact on reconstitution of
HCMV-speciﬁc CD4þ rather than CD8þ T cells; and (4)
reconstitution of systemic HCMV-speciﬁc T cell immunity,
though required for control of HCMV reactivation, does not
prevent late-onset GID in patients with previous GVHD.
As for the ﬁrst point (predominant role of CD4þ T cells in
the control of HCMV infection), 63 HCMV-seropositive adult
HSCT recipients were divided into 3 groups on the basis of
severity of HCMV reactivation and the need for pre-emptive
antiviral treatment. Group 1 included patients able to control
HCMV reactivation without antiviral therapy. Almost all
of these HSCTR rapidly recovered (within 2 months after
E. Gabanti et al. / Biol Blood Marrow Transplant 21 (2015) 2192e22022200transplantation) levels of HCMV-speciﬁc CD4þ T cells
considered as protective (>1 cell/mL blood). This cut-off level
was previously determined by our group in both young and
adult HSCTR [7,11]. Similar cut-off levels have been reported
by others [18].
Group 2 patients did not control HCMV infection spon-
taneously but required a cycle of antiviral therapy when
reaching or approaching the established HCMV DNA cut-off
level during the second month after HSCT. In the majority
of these patients, recovery of HCMV-speciﬁc CD4þ Tcells was
delayed until 3 to 4 months after transplantation.
Group 3 included a minority of patients who underwent
multiple courses of antiviral therapy because of relapsing
systemic HCMV infection, which occurred as a ﬁrst episode at
about the same time as in patients of the other groups. In
many group 3 patients, HCMV-speciﬁc CD4þ T cells were not
yet reconstituted 1 year after transplantation.
It should be noted that the kinetics of HCMV-speciﬁc
CD8þ T cell recovery after transplantation was very rapid,
as CD8þ T cells exceeded the previously supposed [7,11]
protective cut-off level of 3 cells/mL blood within 2 months
after transplantation. Moreover, HCMV-speciﬁc CD8þ T cell
levels were not signiﬁcantly different among the 3 groups of
patients at any time point, although a trend towards a lower
levels of HCMV-speciﬁc CD8þ T cells at day þ60 was
observed in group 3 patients with severe relapsing infection.
This suggests that, in the studied population, the major ac-
tors in the protection against HCMV reactivation were
HCMV-speciﬁc CD4þ T cells and that HCMV-speciﬁc CD8þ
T cells alone did not confer sustained immune control of
virus reactivation. This ﬁnding is in accordance with a recent
study by our group showing that, in a population of sero-
positive solid-organ transplant recipients, long-term pro-
tection from HCMV reactivation was not conferred in the
absence of HCMV-speciﬁc CD4þ T cells [19]. Similarly, levels
of speciﬁc CD4þ, but not CD8þ Tcells, were found to inversely
correlate with reactivation episodes in allogeneic HSCT re-
cipients in a study by Widmann et al. [20]. Moreover, a
deﬁcient HCMV-speciﬁc CD4þ T cell immune response
within the ﬁrst 30 to 50 days after transplantationwas found
to be associated with high risk of viral reactivation after
allogeneic HSCT [21].
As for the second point (better protection conferred by
polyfunctional CD4þ T cells), as many as 7 patients belonging
to group 2 developed HCMV infection requiring antiviral
treatment in the presence of CD4þ T cell levels deﬁned as
protective. In a previous study by our group, the predictive
value of this cut-off was found to be around 80%, indicating
that 20% of patients may still develop severe HCMV infection
in the presence of speciﬁc CD4þ Tcell levels above the cut-off
[7]. Thus, it was investigated whether HCMV-speciﬁc CD4þ
T cells of these patients were functionally different from
CD4þ T cells of group 1 (self-resolving infection) patients. It
was observed that these nonprotected patients had a lower
number of CD4þ T cells producing IL-2 and TNFa together
with IFN-g. These results are in accordancewith the previous
study, in which a lack of IL-2 was observed in HCMV-speciﬁc
CD4þ T cells of nonprotected patients [7]. In the current
study, no differences in the HCMV-speciﬁc CD8þ T cell
cytokine proﬁle were observed between protected and
nonprotected patients, as well as in perforin production by
the same cells (data not shown). As a next step, the analysis
of the expression of exhaustion markers, or the direct eval-
uation of the ability to kill HCMV-infected cells could help in
the search for parameters of protection in CD8þ T cells.In our high-risk seropositive population [21,22], we
studied the impact of different factors on both HCMV reac-
tivation severity and HCMV-speciﬁc CD4þ and CD8þ T cell
reconstitution. Among factors analyzed, donor HCMV sero-
negativity (and, thus, lack of transfer of memory HCMV-
speciﬁc T cells with the graft) was found to play a major
role: all patients able to spontaneously control virus infec-
tion (group 1) received a transplant fromHCMV-seropositive
donors. A correlation with the severity of infection was also
found in patients receiving a transplant from unrelated do-
nors (all receiving ATG in the conditioning regimen), and in
patients receiving high-dose corticosteroids for acute GVHD
treatment, as already reported [23,24]. Instead, patient age
and stem cell source (peripheral blood or bone marrow) had
no affect on the virological outcome. Conﬂicting results have
been provided by other studies [25,26]; however, the num-
ber of patients analyzed in the present study is too low to
draw robust conclusions on this point.
We observed that the same factors inﬂuencing virological
outcome have an impact on reconstitution of HCMV-speciﬁc
CD4þ T cells. From previous studies it is not clear to what
extent these risk factors, particularly high-dose steroid
treatment, could inhibit/delay immune reconstitution of
HCMV-speciﬁc CD4þ rather than CD8þ T cells [4]. One study
reported a negative correlation between the intensity of
immunosuppressive therapy and levels of HCMV-speciﬁc
immunity that appeared to be much more impaired for
CD4þ than CD8þ T cells [16]. On the other hand, in a previous
study on pediatric HSCTR, some patients receiving high-dose
steroids did not show a reduction in the number of HCMV-
speciﬁc CD4þ or CD8þ T cells, although developing a severe
SI [11]. In the current study, treatment with high-dose cor-
ticosteroids for acute GVHD determined a rapid and long-
lasting depletion in HCMV-speciﬁc CD4þ T cells in patients
who subsequently developed severe recurrent infections,
whereas CD8þ T cells were only slightly decreased and
rapidly returned to the presteroid level.Whether the effect of
steroids was related to T cell depletion or their functional
inhibition is not clear. Glucocorticoids were found to block
IL-2 through inhibition of IL-1 and IL-6 genes [27]. In our
study, GVHD treatment also induced a reduction in total
CD4þ T cells (data not shown).
Among the 63 HSCT recipients, 8 patients (13%) suffered
from late-onset HCMV GID, diagnosed at a median of
325 days after transplantation, which was successfully
resolved after prompt antiviral treatment. All of these pa-
tients reactivated HCMV in the ﬁrst weeks after trans-
plantation at variable levels: 3 of them had low HCMV
DNAemia and spontaneously resolved the infection, whereas
the remaining 5 underwent 1 or more courses of antiviral
therapy. At the time of organ infection diagnosis, 6 patients
(75%) showed HCMV-speciﬁc CD4þ T cells in peripheral
blood and all of them had very high levels of HCMV-speciﬁc
CD8þ T cells. Concomitantly, HCMV DNA in blood was un-
detectable or detected at a very low level. The diagnosis of
HCMV GID is often challenging, and the use of additional
techniques would corroborate the diagnosis by PCR.
Although immunohistochemistry was performed, HCMV
nuclear inclusion bodies were not detected in almost all
samples examined. However, as no other possible cause of
GID was detected (ie, active GVHD or other infections), the
high level of virus in the tissue versus its absence or very low
level in blood, and the ex juvantibus proof that GCV resolved
clinical symptoms, indicate HCMV as the major pathogen
involved. We already observed, in patients receiving
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may be associated with high and also with low systemic viral
load [28], and, in lung transplant recipients, we showed that
systemic T cell response may not be sufﬁcient to provide
protection against HCMV pneumonia [29]. Also in this report,
despite the pivotal role of HCMV-speciﬁc CD4þ T cells in the
control of HCMV reactivation, the presence of these cells in
blood was not found to be sufﬁcient in some cases to confer
protection against late-onset end-organ HCMV GID. Inter-
estingly, all patients developing HCMV GID were treated
some months before with high-dose steroids for acute or
chronic GVHD, and the majority of them received a trans-
plant from a HCMV-seronegative donor. Occurrence of GVHD
has been reported to be an important risk factor for the
development not only of HCMV viremia but also of HCMV
GID [30]. Whether this is the consequence of an impaired
T cell response due to prolonged steroid therapy or a local
effect of allogeneic stimulation during GVHD leading to
HCMV reactivation [31,32] still needs to be clariﬁed. How-
ever, we did not observe a signiﬁcant impairment of systemic
immunity in patients suffering from HCMV GID disease.
Investigation of local (tissue) T cell immunity would be of
help in understanding the pathogenesis of GID in these
patients.
In conclusion, our results suggest that reconstitution of
HCMV-speciﬁc CD4þ T cells is pivotal for control of HCMV
reactivation after HSCT and that CD8þ T cells alone do not
confer sustained immune control of HCMV infection. This
implies that measurement of HCMV-speciﬁc CD4þ T cells
alone might be sufﬁcient to predict whether a patient is at
risk of HCMV reactivation or not, whereas testing levels of
HCMV-speciﬁc CD8þ T cells alone appears to be prognosti-
cally inadequate. Thus, monitoring of HCMV-speciﬁc CD4þ
T cell reconstitution can help in assessing the time lapse after
HSCT in which the patient is at risk for HCMV infection/dis-
ease and should be monitored for HCMV in blood to start
timely pre-emptive treatment, when required. After speciﬁc
CD4þ recovery, HCMV monitoring in blood could be dis-
continued. At the same time, speciﬁc CD4þ T cells are more
susceptible than CD8þ to high-dose steroid treatment for
GVHD. Thus, strict virological/immunological monitoring is
further required in these patients, continuing after immune
reconstitution has occurred. Patients showing a sustained
lack of HCMV-speciﬁc CD4þ T cells could take advantage of
adoptive HCMV-speciﬁc T cell immunotherapy to avoid
repeated HCMV recurrences.
Finally, patients with GVHD (intestinal or not) should also
be considered high-risk for developing late HCMV GID, even
in the presence of protective systemic HCMV-speciﬁc CD4þ
Tcell immunity and with the absence of HCMVDNA in blood.
Thus, with currently available tools, virological and immu-
nological monitoring in blood are not useful in the case of
HCMV GID and GI biopsies should be considered for the
differential diagnosis of HCMV GID in HSCTR with GI clinical
symptoms. Moreover, the ex vivo study of the anti-HCMV
activity of tissue-inﬁltrating T cells obtained from organ bi-
opsies will represent a step forward in our understanding of
HCMV control by the reconstituting immune system in HSCT.
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